Cargando…

Favorable Management of Repeated Serous Retinal Detachment with Continued Tumor Response in a Patient with Intrahepatic Cholangiocarcinoma during Treatment with Pemigatinib

Pemigatinib is a fibroblast growth factor receptor inhibitor (FGFRi) approved for the treatment of patients with previously treated biliary tract cancer with FGFR2 fusion. Although infrequent, ocular toxicity manifested as serous retinal detachment (SRD) has been observed and is regarded as a seriou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yukutake, Masanobu, Sekito, Tsuyoshi, Yamakita, Ichiko, Itakura, Hideki, Kabu, Koki, Nagata, Shinji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183291/ https://www.ncbi.nlm.nih.gov/pubmed/35945011 http://dx.doi.org/10.2169/internalmedicine.0150-22

Ejemplares similares

Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress
por: Gadaleta-Caldarola, Gennaro, et al.
Publicado: (2022)

Pemigatinib for cholangiocarcinoma
Publicado: (2022)

Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling test
por: Ishido, Shun, et al.
Publicado: (2023)

Multifocal serous retinopathy with pemigatinib therapy for metastatic colon adenocarcinoma
por: Alekseev, Oleg, et al.
Publicado: (2021)

Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants
por: Lin, Qianmeng, et al.
Publicado: (2022)

Case Report: Persistent response to combination therapy of pemigatinib, chemotherapy, and immune checkpoint inhibitor in a patient with advanced intrahepatic cholangiocarcinoma
por: Zhang, Zhuochao, et al.
Publicado: (2023)

Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements
por: Walden, Daniel, et al.
Publicado: (2022)

Clinical experience with pemigatinib for previously treated metastatic cholangiocarcinoma: practical considerations from clinical cases
por: Wadsley, Jonathan, et al.
Publicado: (2023)

Population pharmacokinetic and exposure‐response analyses of pemigatinib in patients with advanced solid tumors including cholangiocarcinoma
por: Gong, Xiaohua, et al.
Publicado: (2023)

A new promising oncogenic target (p.C382R) for treatment with pemigatinib in patients with cholangiocarcinoma
por: Hempel, Louisa, et al.
Publicado: (2022)

Hyperphosphatemic Tumoral Calcinosis With Pemigatinib Use
por: Puar, Akshan, et al.
Publicado: (2022)

FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements
por: Bekaii-Saab, Tanios S, et al.
Publicado: (2020)

Bilateral serous retinal detachment in pre-eclampsia a rare but favorable complication: case report
por: Benlghazi, Abdelhamid, et al.
Publicado: (2023)

Impact of JMJD6 on intrahepatic cholangiocarcinoma
por: Kosai-Fujimoto, Yukiko, et al.
Publicado: (2022)

Population Pharmacokinetics Analysis of Pemigatinib in Patients With Advanced Malignancies
por: Ji, Tao, et al.
Publicado: (2022)

Intrahepatic Sarcomatoid Cholangiocarcinoma
por: Malhotra, Shalini, et al.
Publicado: (2010)

Asbestos and Intrahepatic Cholangiocarcinoma
por: Brandi, Giovanni, et al.
Publicado: (2020)

Management of Intrahepatic Cholangiocarcinoma
por: Kodali, Sudha, et al.
Publicado: (2021)

PIMASERTIB AND SEROUS RETINAL DETACHMENTS
por: AlAli, Alaa, et al.
Publicado: (2016)

Intrahepatic cholangiocarcinoma with clear cell type following laparoscopic curative surgery
por: Yamamoto, Takuya, et al.
Publicado: (2020)

Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration
por: Chen, Zi-Rong, et al.
Publicado: (2023)

Changes in Choroidal Thickness and Structure in Preeclampsia with Serous Retinal Detachment
por: Fukui, Ayumi, et al.
Publicado: (2023)

Successful Resection of Solitary Abdominal Wall Metastasis of Sarcomatous Intrahepatic Cholangiocarcinoma
por: Ono, Kosuke, et al.
Publicado: (2019)

FIGHT‐102: A phase 1 study of pemigatinib in Japanese patients with advanced malignancies
por: Fujiwara, Yutaka, et al.
Publicado: (2023)

Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study
por: Shi, Guo‐Ming, et al.
Publicado: (2022)

Prognosis of the intrahepatic cholangiocarcinoma after resection: hepatitis B virus infection and adjuvant chemotherapy are favorable prognosis factors
por: Liu, Rui-qing, et al.
Publicado: (2013)

Two Varieties of Intrahepatic Cholangiocarcinoma
por: Nagorney, David M.
Publicado: (1994)

Intrahepatic Cholangiocarcinoma with Sarcomatous Changes
por: Inoue, Yoshiyuki, et al.
Publicado: (2012)

Serum Markers of Intrahepatic Cholangiocarcinoma
por: Malaguarnera, Giulia, et al.
Publicado: (2013)

Intrahepatic cholangiocarcinoma: current perspectives
por: Buettner, Stefan, et al.
Publicado: (2017)

Intratumoral heterogeneity of intrahepatic cholangiocarcinoma
por: Walter, Dirk, et al.
Publicado: (2017)

Molecular heterogeneity in intrahepatic cholangiocarcinoma
por: Ahn, Keun Soo, et al.
Publicado: (2020)

Recurrent Intrahepatic Cholangiocarcinoma – Review
por: Bekki, Yuki, et al.
Publicado: (2021)

Stereotactic radiotherapy for intrahepatic cholangiocarcinoma
por: Borakati, Aditya, et al.
Publicado: (2022)

Surgical Aspects of Intrahepatic Cholangiocarcinoma
por: Kupietzky, Amram, et al.
Publicado: (2022)

Locoregional Therapy for Intrahepatic Cholangiocarcinoma
por: Owen, Mackenzie, et al.
Publicado: (2023)

Bilateral Serous Retinal Detachment in Pregnancy
por: Phang, Daniel Sen Kai, et al.
Publicado: (2022)

Maffucci Syndrome with Intrahepatic Cholangiocarcinoma: A Case Report
por: Kobayashi, Ryoichiro, et al.
Publicado: (2021)

Periostin promotes malignant potential by induction of epithelial‐mesenchymal transition in intrahepatic cholangiocarcinoma
por: Mino, Masaaki, et al.
Publicado: (2017)

A Successfully Treated Case of Intrahepatic Cholangiocarcinoma with Exacerbation of Dermatomyositis
por: Yasuda, Jungo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_v61n2nc9u0vsafc11emsq38kri